1.	Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: DSMM V, NCT00546988
2.	Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SOGUG-2010-01, NCT01513187
3.	Phase II Randomized Study of Dynamic Contrast-Enhanced MRI Assessment of Vascular Changes Induced With Bevacizumab Alone Versus in Combination With Recombinant Interferon Alpha-2a in Patients With Previously Untreated Stage III-IV Renal Cell Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MTVERNHOSP-RD2007-114, RD 2007-114, ENH-RD2007-114, EUDRACT-2008-006414-19, EU-20917, NCT00873236
4.	Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-560, NCT01294618
5.	Pegasys in Patients With Chronic Myeloid Leukemia (CML) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2011-0184, NCT01392170
6.	An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25255, NCT01392729